Acquisitions - Schedule of Supplemental Pro Forma Financial Information (Details) - Horizon Therapeutics - USD ($) $ in Millions |
12 Months Ended | |
|---|---|---|
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Business Combination [Line Items] | ||
| Total revenues | $ 30,969 | $ 29,964 |
| Net income | $ 5,383 | $ 2,381 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after tax, of pro forma income (loss) of combined entity as if acquisition date of business combination occurred as of beginning of period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of pro forma revenue of combined entity as if acquisition date of business combination occurred as of beginning of period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|